| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/18/2008 | US20080227734 Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment |
| 09/18/2008 | US20080227706 Polypeptides and polynucleotides; genetic engineering; medical diagnosis; treatment of infection causes sepsis, meningitis, pneumonia, cellulitis, osteomyelitis, septic arthritis, endocarditis or epiglottis; bacterial protein antigen vaccine |
| 09/18/2008 | US20080227704 CXCL13 binding proteins |
| 09/18/2008 | US20080227702 Providing an osteogenic protein in a biocompatible bioresorbable carrier to defect locus, thereby inducing formation of functional replacement cartilage tissue; medical device for repairing a defect in an intervertebral disc |
| 09/18/2008 | US20080227695 reduced expression and/or function of Dlg (discs large) is an important factor for tumor formation; measuring the expression and/or function of Dlg |
| 09/18/2008 | US20080227690 Particles for inhalation having rapid release properties |
| 09/18/2008 | US20080227685 Polypeptide comprising the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:125); activating guanylate cyclase C (GC-C) receptor; gastroesophageal reflux disease, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, dyspepsia, constipation |
| 09/18/2008 | US20080227200 Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same |
| 09/18/2008 | US20080227135 Autoimmune Conditions and NADPH Oxidase Defects |
| 09/18/2008 | US20080227129 Using multimeric ubiquitin fusion protein as an enzyme activity indicator; destruction of reporter demonstrate enhanced enzyme activity |
| 09/18/2008 | US20080227082 Method of identifying a mhc class i restricted t cell response |
| 09/18/2008 | US20080226759 System for treating addictions |
| 09/18/2008 | US20080226758 Formulation for improving lipoprotein profiles in mammals comprising at least one processed Morinda citrifolia product present in amount by weight of 0.1-99 percent; for reducing LDL lipoprotein levels, increasing HDL lipoprotein levels, decreasing absorption of fatty acid across intestinal epithelium |
| 09/18/2008 | US20080226746 Vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, vitamin D3, vitamin C, vitamin E, niacin, copper, magnesium, zinc, and iron |
| 09/18/2008 | US20080226742 Non-porous microparticles comprising hydrophobic polymer and plasticizer; controlled release |
| 09/18/2008 | US20080226738 Sustained-Released Pellet Formulation of Alpha1-Receptor Antagonist and Process For the Preparation Thereof |
| 09/18/2008 | US20080226732 Nanoparticulate compositions of angiogenesis inhibitors |
| 09/18/2008 | US20080226730 Particles for inhalation having rapid release properties |
| 09/18/2008 | US20080226722 Gel Composition Comprising Charged Polymers |
| 09/18/2008 | US20080226716 Gamma aminobutyric acid antagonist such as naphthylalanine; antiepileptic agents; antidepressants; anxiolytic agents; psychological disorders; neurodegenerative diseases; analgesics; drug withdrawal |
| 09/18/2008 | US20080226698 Amorphous drug transdermal systems, manufacturing methods, and stabilization |
| 09/18/2008 | US20080226689 Apparatus for uniform delivery of drugs to biological systems |
| 09/18/2008 | US20080226666 Immunogenic polypeptide for protecting pigs against viral infection or postweaning multisystemic wasting syndrome |
| 09/18/2008 | US20080226654 Uses of mammalian cytokine; related reagents |
| 09/18/2008 | US20080226652 Rabies virus G protein specific immunoglobulin for use in prevention and treatment viral infection |
| 09/18/2008 | US20080226648 Using cysteamine compound to treat immunological disorders |
| 09/18/2008 | US20080226646 Use of biomolecular targets in the treatment and visualization of tumors |
| 09/18/2008 | US20080226636 Novel human ulip/CRMP protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/18/2008 | US20080226635 Transmembrane receptor specific immunoglobulin for use in targeting and destroying pancreatic, lung and/or breast cancers |
| 09/18/2008 | US20080226632 Cell growth factor specific immunoglobulin for treatment and prevention of cell proliferative and skin disorders |
| 09/18/2008 | US20080226630 Recombinant antibodies for treatment of respiratory syncytial virus infections |
| 09/18/2008 | US20080226623 Stabilized protein crystals, formulations comprising them and methods of making them |
| 09/18/2008 | US20080226602 RNA viral vector for use in targeting tumor cell for destruction; antitumor agents and gene therapy |
| 09/18/2008 | US20080226600 Adeno-associated viruses and uses thereof |
| 09/18/2008 | US20080226599 Methods of treatment involving p21/CIP1 |
| 09/18/2008 | US20080226598 Dendritc specific RNA viral plasmid comprising nucleotide sequences coding tumor associated for use in developing cancer vaccine; genetic vaccines |
| 09/18/2008 | US20080226562 Stable optical imaging in vitro, in vivo; magnetic resonance imaging ; metal oxide core overcoated with polymer and chromogen |
| 09/18/2008 | US20080226560 Supplying cargo compound into cancer cells; cargo compound may be nucleic acids, Dna, Rna |
| 09/18/2008 | US20080226556 Using macrophages;milk fat globulins; epidermal growth factor mutants |
| 09/18/2008 | US20080226552 Automated Radiolabelling Method |
| 09/18/2008 | US20080226551 Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides |
| 09/18/2008 | DE102004045187B4 Wirkstoffe zur Überführung von inaktivem TGFb-latent in aktiven TGFb und deren Verwendung in kosmetischen und pharmazeutischen Zusammensetzungen Agents for the conversion of inactive latent TGFb in active TGFb and their use in cosmetic and pharmaceutical compositions |
| 09/18/2008 | CA2680280A1 Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same |
| 09/18/2008 | CA2680236A1 Protective agents for transplanted organs |
| 09/18/2008 | CA2680122A1 Pharmaceutical composition |
| 09/18/2008 | CA2679971A1 Glucokinase activator |
| 09/17/2008 | EP1970438A1 Pasteurisation process for microbial cells and microbial oil |
| 09/17/2008 | EP1970383A1 Compounds and methods for modulating nonclassical cadherin-mediated functions |
| 09/17/2008 | EP1970374A1 Process for the production of substituted 2-(pyridin-2-ylmethylsulfinyl)-1H-benzimidazoles |
| 09/17/2008 | EP1970373A1 Alicyclic heterocyclic compound |
| 09/17/2008 | EP1970370A1 Amorphous form of 1,2-dihydropyridine compound |
| 09/17/2008 | EP1970068A1 Tissue repair using multipotent cells |
| 09/17/2008 | EP1970058A1 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 09/17/2008 | EP1969951A2 Compositions against inflammatory processes |
| 09/17/2008 | EP1968634A2 IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES AND OF POLYREACTIVE IgGs |
| 09/17/2008 | EP1968570A2 Isoflavones for treating mucopolysaccharidoses |
| 09/17/2008 | EP1447400B1 Bicyclic compound |
| 09/17/2008 | EP1414947B1 Multipotent stem cells from peripheral tissues and uses thereof |
| 09/17/2008 | EP1411968B1 Glp-1 exendin-4 peptide analogs and uses thereof |
| 09/17/2008 | EP1409477B1 Piperidine derivatives as nmda receptor antagonists |
| 09/17/2008 | EP1325910B1 Aliphatic nitrogenous five-membered ring compounds |
| 09/17/2008 | EP1307450B1 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones |
| 09/17/2008 | EP1245676B1 Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof |
| 09/17/2008 | EP1202736B1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 09/17/2008 | EP1200555B1 Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
| 09/17/2008 | EP1036095B1 Oxygen-transporting albumin-based blood replacement composition and blood volume expander |
| 09/17/2008 | EP0712303B2 Skin patches comprising testosterone and optionally estrogen |
| 09/17/2008 | CN101267819A Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use thereof |
| 09/17/2008 | CN101265285A Immunostimulatory nucleic acid molecules |
| 09/17/2008 | CN101264307A Common ginger root compound peptide composition and preparation thereof |
| 09/17/2008 | CN101264292A Medicaments assembly for replenishing and nourishing yin, tonifying kidney and promoting digestion and preparation thereof |
| 09/17/2008 | CN101264274A Medicaments assembly for treating night sweat of the young and middle-aged and preparation thereof |
| 09/17/2008 | CN101264234A Orally-administered medicament for treating deficiency of qi and blood type dizziness |
| 09/17/2008 | CN101264229A Medicaments assembly for nourishing blood and nourishing heart, promoting blood and qi circulation and preparation thereof |
| 09/17/2008 | CN101264119A Medicine for treating hernia and preparation thereof |
| 09/17/2008 | CN101264073A Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 09/17/2008 | CN101264072A Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 09/17/2008 | CN101264051A Modified release pharmaceutical formulation |
| 09/17/2008 | CN100418977C Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 09/17/2008 | CN100418968C Pirazino(aza)indole derivatives |
| 09/17/2008 | CN100418967C Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 09/17/2008 | CN100418965C Imidazopyridine derivatives |
| 09/17/2008 | CN100418955C Novel Benzo-fused heterocycles |
| 09/17/2008 | CN100418951C Cycloamine derivative and its use as medicine |
| 09/17/2008 | CN100418584C Method and arrangement for producing contrast agent for magnetic resonance imaging |
| 09/17/2008 | CN100418533C Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 09/17/2008 | CN100418527C Improved pharmaceutical formulations |
| 09/16/2008 | US7425642 Anti-diabetic activity, improves insulin resistance and control the blood glucose level more safely, simulates activity of peroxisome proliferator-activated receptor; (1-{(2E)-3-[3-(Bromomethyl)phenyl]prop-2-en-1-yl}-1H-pyrrol-2-yl)(4-methyl-phenyl)methanone |
| 09/16/2008 | US7425641 Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions |
| 09/16/2008 | US7425637 mitogen-activated protein/extracellular signal-regulated (MAP/ERK)Kinase pathways; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; hyperproliferative diseases; anticarcinogenic and antiinflammatory agent |
| 09/16/2008 | US7425610 Expression vector comprising nucleotide sequences coding novel receptor protein for use in prevention and treatment of cell proliferative and autoimmune disorders |
| 09/16/2008 | US7425578 Immunoregulatory compounds and derivatives and methods of treating diseases therewith |
| 09/16/2008 | US7425568 Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 09/16/2008 | US7425567 Inhibitor of phosphodiesterase enzyme, 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid monohydrate; treating inflammatory diseases, diabetics, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, Parkinson's disease, dementia; chemical intermediates |
| 09/16/2008 | US7425563 Excellent poly (ADP-ribose) synthetase inhibitors; various ischemic diseases, inflammatory diseases, neurodegenerative diseases, diabetes, septic shock, cephalic injury; 1,2-Dihydro-4-[4-(dimethylaminomethyl)phenyl]-5-hydroxy-1-oxoisoquinoline |
| 09/16/2008 | US7425562 Inhibitors of cruzipain and other cysteine proteases |
| 09/16/2008 | US7425559 Medicine containing pyrimidine derivative |
| 09/16/2008 | US7425555 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 09/16/2008 | US7425554 1,2-di(cyclic)substituted benzene compounds |
| 09/16/2008 | US7425549 Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |